Lung Cancer News and Research

Latest Lung Cancer News and Research

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

13 Dec 2010

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

13 Dec 2010

No safe level of exposure to secondhand smoke

The following is a statement by Cheryl G. Healton, DrPH, President and CEO of Legacy on the U.S. Surgeon General's Report:

13 Dec 2010

Cancer researchers identify six gene markers in early stage NSCLC

Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

Study shows stereotactic radiation therapy as effective as surgery in elderly patients with early-stage lung cancer

A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

13 Dec 2010

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.

10 Dec 2010

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

People exposed to North Dakota road materials face increase risk of developing mesothelioma

New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

10 Dec 2010

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

10 Dec 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

Tobacco-cessation expert receives 2011 ASPO Joseph W. Cullen Memorial Award tobacco research

Behavioral scientist and tobacco-cessation expert, Alexander V. Prokhorov, M.D., Ph.D., at The University of Texas MD Anderson Cancer Center is the recipient of the 2011 American Society of Preventive Oncology (ASPO) Joseph W. Cullen Memorial Award for Excellence in Tobacco Research.

10 Dec 2010

Collegium Ramazzini repeats calls for total global ban on all asbestos

Scientists at the Collegium Ramazzini in Modena, Italy have repeated calls for a total ban on all asbestos across the globe. Writing in the International Journal of Environment and Health, the Collegium points out that just 52 nations have banned asbestos but a large number still use, import and export asbestos and asbestos-containing products.

9 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

Smoking cessation products available on PBS

Australia’s federal government has announced that it will subsidize the cost of nicotine patches to help smokers quit. The announcement was made by Health Minister Nicola Roxon on Thursday who said that concession card holders would be able to access Nicorette, Nicabate P and Nicotinell under the Pharmaceutical Benefits Scheme (PBS) from February 1, 2011. She said, “Cancer scars the lives of too many Australians and we know that reducing the smoking rate is one of the most effective ways to reduce the rate of death from this terrible disease.” Anti-smoking drug Varenicline (Champix) would also be available for willing quitters.

8 Dec 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Syndax reports promising results from entinostat preclinical studies in breast cancer

No safe level of exposure to secondhand smoke

Cancer researchers identify six gene markers in early stage NSCLC

Research programs embody the promise of anti-aging medicine.

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Study shows stereotactic radiation therapy as effective as surgery in elderly patients with early-stage lung cancer

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

People exposed to North Dakota road materials face increase risk of developing mesothelioma

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Tobacco-cessation expert receives 2011 ASPO Joseph W. Cullen Memorial Award tobacco research

Collegium Ramazzini repeats calls for total global ban on all asbestos

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Smoking cessation products available on PBS

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in